Urgent statement on antithrombotic therapy of atrial fibrillation

Circulation Journal

Volumn 75, Issue 12, 2011, Pages 2719-2721

  Ogawa, Satoshi ^a   Hori, Masatsugu ^b  

^a Joint Working Groups for the Guidelines for Pharmacotherapy of Atrial Fibrillation ^*  (Japan)

^b and Antiplatelet Therapy in Cardiovascular Disease (JCS 2009)   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; DABIGATRAN; FRESH FROZEN PLASMA; THROMBIN INHIBITOR; WARFARIN;

BLEEDING; BRAIN INFARCTION; CARDIOVERSION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRACARDIAC THROMBOSIS; JAPAN; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NOTE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOOTH EXTRACTION;

ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINES AS TOPIC; HUMANS; JAPAN; MALE;

EID: 82555195201     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-88-0026     Document Type: Note

References (10)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
2. Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation: Sub-analysis in Japanese population in RE-LY trial. Circ J 2011; 75: 800-805.
3. Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, et al; American College of Cardiology Foundation/ American Heart Association Task Force. 2011 ACCF/AHA/ HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123: 1144-1150.
4. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011; 27: 74-90.
5. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
6. Oldgren J, Alings M, Darius H, Eikelboom J, Ezekowitz M, Parekh A, et al. Dabigatran versus warfarin in atrial fibrillation patients with low, moderate, and high CHADS2 Score: A RE-LY subgroup analysis. Presented at the 59th Annual Scientific Session of the American College of Cardiology, 15th March 2010.
7. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al; Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006; 27: 1979-2030.
8. Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, et al. Antithrombotic therapy in atrial fibrillation: Evaluation and positioning of new oral anticoagulant agents. Circ J 2011; 75: 1539-1547.
9. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136.
10. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, et al. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-810.